Keyphrases
Tumor
78%
Dutch
57%
Pediatric
40%
Childhood Cancer Survivors
39%
Pediatric Patients
35%
Pediatric Leukemia
33%
Acute Lymphoblastic Leukemia
32%
Overall Survival
30%
Wilms Tumor
29%
Acute Myeloid Leukemia
29%
Neuroblastoma
27%
Children with Cancer
27%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
High Risk
25%
Childhood Cancer
24%
Pediatric Oncology
23%
Netherlands
23%
Event-free Survival
22%
Confidence Interval
19%
Older Adults
19%
Graft-versus-host Disease (GvHD)
18%
Glioblastoma
18%
Glioma
18%
Health-related Quality of Life
17%
Pediatric Acute Lymphoblastic Leukemia
17%
Chemotherapy
17%
Hematopoietic Stem Cell Transplantation
17%
Melanoma
17%
Central Nervous System Tumors
17%
Diffuse Intrinsic Pontine Glioma
16%
Working Diagnosis
16%
Meta-analysis
16%
Cancer Treatment
15%
Hematopoietic Cell Transplantation
15%
Oncology
15%
Survivors
15%
Childhood Acute Lymphoblastic Leukemia
15%
Radiotherapy
14%
Minimal Residual Disease
14%
Pediatric Cancer Patients
14%
Risk Factors
14%
Pheochromocytoma
13%
T Cells
13%
Cancer Types
13%
Tumor Subtype
13%
Clinical Practice Guidelines
12%
Diffuse Glioma
12%
Paraganglioma
12%
Prognostic Factors
12%
Leukemia
11%
Cancer Genome Atlas
11%
Phase II Trial
11%
Survival Rate
11%
Clinical Outcomes
11%
Hazard Ratio
11%
Pediatric Cancer
11%
High-risk Neuroblastoma
10%
Childhood Cancer Survivor Study
10%
Leukemia Patients
10%
Randomized Controlled Trial
10%
Molecular Analysis
10%
Pharmacokinetics
9%
Adjuvant Therapy
9%
Isocitrate Dehydrogenase 1 (IDH1)
9%
Newly Diagnosed
9%
In Cancer
9%
Clinical Trials
9%
Renal Tumor
9%
Medulloblastoma
9%
Vincristine-induced Peripheral Neuropathy
9%
Late Effects
9%
Systematic Meta-analysis
9%
Population Pharmacokinetics
9%
European Organizations
9%
Risk Stratification
9%
Treatment Outcome
8%
Molecular Characterization
8%
Relapsed or Refractory Acute Myeloid Leukemia
8%
Relapsed or Refractory
8%
Pediatric Renal Tumors
8%
Immunohistochemistry
8%
Odds Ratio
8%
COVID-19 Pandemic
8%
Phase II Study
8%
Targeted Therapy
8%
Healthcare Professionals
8%
Adult Cancer
7%
Pembrolizumab
7%
BCP-ALL
7%
Renal Cell Carcinoma
7%
DNA Methylation (DNAm)
7%
Pediatric Tumors
7%
RNA Sequencing (RNA-seq)
7%
Programmed Death-ligand 1 (PD-L1)
7%
Stage III Melanoma
7%
Antithymocyte Globulin
7%
Population-based Study
7%
Improved Outcomes
7%
COVID-19
7%
Immune Reconstitution
7%
Medicine and Dentistry
Neoplasm
100%
Pediatrics
78%
Childhood Cancer
76%
Malignant Neoplasm
71%
Acute Lymphoblastic Leukemia
40%
Disease
39%
Acute Myeloid Leukemia
34%
Diagnosis
33%
Ganglioneuroblastoma
32%
Wilms' Tumor
31%
Nodular Melanoma
28%
Pediatrics Patient
28%
Overall Survival
27%
Pediatric Acute Myeloid Leukemia
25%
Ganglioglioma
24%
Systematic Review
23%
Immunotherapy
23%
Oncology
22%
Event Free Survival
20%
Kidney Tumour
20%
Pediatric Cancer
18%
Recurrent Disease
17%
Hematopoietic Stem Cell Transplantation
17%
Adolescent
16%
Central Nervous System Tumor
15%
Minimal Residual Disease
15%
Hematopoietic Stem Cell
14%
Radiation Therapy
14%
Glioblastoma
13%
Biological Marker
13%
Clinical Trial
13%
Quality of Life
13%
Leukemia
13%
B Cell
13%
Survival Rate
12%
T Cell
12%
Cell Transplantation
11%
Precursor
11%
Dexamethasone
11%
Central Nervous System
11%
Cancer Treatment
11%
Cancer
11%
COVID-19
11%
Risk Stratification
10%
Pheochromocytoma
10%
Hazard Ratio
10%
Paraganglioma
10%
Magnetic Resonance Imaging
9%
Rhabdomyosarcoma
9%
Adjuvant Therapy
9%
Prognostic Factor
9%
Organoid
9%
Immunohistochemistry
9%
Targeted Therapy
9%
Pontine Glioma
9%
Meta-Analysis
8%
Adverse Event
8%
Surgery
8%
Cancer Therapy
8%
DNA Methylation
8%
Metastatic Carcinoma
8%
Gene Expression
8%
Pembrolizumab
8%
Supportive Care
7%
Medulloblastoma
7%
Transplantation
7%
Randomized Controlled Trial
7%
Vincristine
7%
Cohort Analysis
7%
Retrospective Study
7%
Acute Myelogenous Leukemia
7%
Soft Tissue Sarcoma
7%
Odds Ratio
7%
In Vitro
7%
RNA Sequence
6%
Breast Cancer
6%
Tumor Cell
6%
Late Effect
6%
Placebo
6%
Fertility Preservation
6%
Cord Blood Stem Cell Transplantation
6%
Retrospective Cohort Study
6%
Clear Cell Renal Cell Carcinoma
6%
Prevalence
6%
Methylation
6%
Tumor Microenvironment
6%
Gene Fusion
5%
Morphology
5%
Cancer Cell
5%
The Cancer Genome Atlas
5%
Infection
5%
Ex Vivo
5%
Low and Middle Income Countries
5%
Neuro-Oncology
5%
Arm
5%
Distant Metastasis
5%
Stem Cell
5%
Recurrence Free Survival
5%
Systemic Therapy
5%
Sarcoma
5%